INTRODUCTION
============

There is a clinical need for improved non-invasive means to diagnose and predict the course of autoimmune thrombocytopenia (ITP). As the cause of elevated platelet-associated IgG (PA-IgG) in multiple thrombocytopenic states is still unclear, such tests have been considered unnecessary and even inappropriate for establishing the diagnosis of TP ([@b32]; [@b10]). A part of the problem could reflect the variation of platelet size in thrombocytopenic patients ([@b14]; [@b13]; [@b15]).

Forward scatter signal distributions of platelets (FSC) in flow cytometry have been presented as fairly comparable with platelet size distributions as determined by hematology cell counter ([@b13]). Although flow cytometry has been applied for the detection of PA-IgG ([@b12]; [@b13]; [@b22]; [@b1]; [@b25]; [@b11]), little attention has been paid to platelet size in the same measurement ([@b13]).

Glycoprotein (GP)-specificity of platelet-associated autoantibodies can be determined by antigen-specific assays, such as monoclonal antibody-specific immobilization of platelet antigen assay (MAIPA; [@b20]), and radioactive immunobead assay ([@b30]). Tomer and collaborators reported that the presence of ITP was highly probable (\>90%) if the antigen-specific assay was positive ([@b36]). However, a negative assay does not rule out the diagnosis ([@b28]; [@b36]). Antigen-specific assays may be also useful in other thrombocytopenic patients than ITP ([@b29]) and may be taken as the gold standard of platelet autoantibody assays.

The aims of the present study were (i) to characterize the normal reference ranges for PA-IgG and platelet size of a PA-IgG assay where results were obtained by flow cytometry, (ii) to study the correlation of platelet size with PA-IgG and (iii) to detect GP-specific autoantibodies with an independent assay in the patients with increased PA-IgG and (iv) to study whether the GP-specific autoantibodies were present more frequently in patients with platelets larger than normal.

MATERIALS AND METHODS
=====================

Patient samples
---------------

Samples from 854 thrombocytopenic patients were screened for PA-IgG. 206 samples with increased PA-IgG \[mean fluorescence intensity (MFI) cut-off value above 300 as determined by mean+2s of healthy controls\] formed the study population tested for GP-specific autoantibodies ([Figure 1](#fig01){ref-type="fig"}). Amongst other data, the lowest (nadir) and the actual platelet count were requested in the sample referrals. Although most referrals included suspected ITP, the clinical condition was multifactorial in most of cases. Thus, these patients were background patient material of this study. The focus, however, was on platelet size and GP-specific PA-IgG.

![Distribution of consequent patient samples according to screening for platelet-associated IgG (PA-IgG) and results of further determination of glycoprotein (GP)-specificity of PA-IgG.](clh0029-0433-f1){#fig01}

Healthy controls
----------------

Samples from 112 controls were obtained from healthy volunteer blood donors and handled similarly to the patient samples. One sample was included in each run (see Controls).

Measurement of PA-IgG
---------------------

Venous blood was collected in three 10 ml EDTA tubes (Venoject, Terumo 288267 or Vacutainer, Becton Dickinson 368457; Becton Dickinson, Franklin Lakes, NJ, USA), which were transported at room temperature. The samples were handled within 24 h.

PA-IgG analysis was performed as a screening method as described earlier ([@b4]; [@b1]; [@b16]). The analyses were performed using a FACScan flow cytometer and Cell Quest program, version 3.1f (Becton Dickinson, Mountain View, CA, USA). To enable analysis of thrombocytopenic samples, no more than 5000 cells were investigated from each sample. If necessary, the gate was adjusted daily according to the healthy control sample. The mean FSC and MFI of PA-IgG were recorded.

To analyze if platelets of different size in a single sample had different amounts of PA-IgG, the platelet scatter in FSC/SSC plot was divided into five consecutive gates (R1--R5). Altogether, 54 randomly selected samples were analyzed for PA-IgG using these gates (samples from patients with large, *n* = 27, with normal, *n* = 22, and with small platelets, *n* = 5). R3 was set to include 50% of events and both R2 and R4 20%. R1 and R5 were set to include events outside R2--R4 ([Figure 2](#fig02){ref-type="fig"}).

![Platelet populations gated according to platelet size (forward scatter, FSC). Five regions of platelets from a healthy control sample in FSC/SSC (side scatter) dot plot were set: R3 to include 50% of events, both R2 and R4 20%, and R1 and R5 events left outside R2--R4.](clh0029-0433-f2){#fig02}

### Controls

The preanalytical factors were covered by the use of controls, which were handled strictly in the same way as patient samples to minimize the influence of, e.g. whole blood storage prior to preparation ([@b11]), EDTA ([@b27]; [@b24]; [@b34]; [@b33]), and fixation with formaldehyde ([@b9]). The influence of preventive maintenance of flow cytometry on the precision of the assay was minimized by analyzing the controls and at least 10 patient samples before and after maintenance. The parameter settings were adjusted if there was a systematic difference of \>3% (three times during 5 years).

A sample from a random healthy donor was used as a control to check all steps of analysis, and to follow the stability of the cut-off level. A strong positive control was used to monitor the linearity and stability of the measurement at high levels of PA-IgG. It controlled the analysis from the step of labeling of the platelets to the measurement. The control was prepared by incubating a pooled platelet preparation from six blood group O donors with 1 : 2 diluted serum containing strong anti-HPA-1a antibodies. The dilution level of anti-HPA-1a serum was chosen so that the PA-IgG result of the control would be as high as possible but still within the linear region of the fluorescence (data not shown). The same batch was used for up to 1 year.

A cut-off (positive) control was used to monitor the linearity and stability of the measurement near the positive (cut-off) level. The control was prepared by incubating a pooled platelet preparation from six blood group O donors with 1 : 64 dilution of the same serum as for the strong positive control. The same batch was used for up to 1 year. A new batch of all controls in the same series was compared to the previous batch for three to five times to establish new target values. Only one control was changed at a time.

GP-specific PA-IgG by direct MAIPA
----------------------------------

GP-specific PA-IgG was measured by direct MAIPA as originally described ([@b20]) and recently by us ([@b17]). For measurement of GP IIbIIIa and/or IbIX specific antibodies, 25 mgrl of platelet suspension (1000 × 10^9^ cells/l) was incubated for 30 min at 37 °C with 0.2 mgrg of two monoclonal antibodies in a single tube, one specific for the GP Ib agr (AP1) and the other specific for the GP IIb-IIIa (AP2; both generous gifts from Doctors Kunicki and Montgomery, Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA). In the separate measurement of GP V-specific antibodies, 80 mgr l of thawed platelet suspension (1000 × 10^9^ cells/l) was incubated with 0.2 mgr g of monoclonal antibody specific for GP V (SW16, CLB, Netherlands). The secondary antibody was an affinity-purified goat antihuman IgG, Fc-specific, peroxidase labeled (Jackson 109-035-098; Suffolk, UK). The absorbances were measured at 492 nm with a spectrophotometer applying special software (Multiscan EX, Thermo Electron Corporation, Vantaa, Finland). To enable inter- and intralaboratory comparisons, the absorbance values of patient samples were divided by the absorbance of a negative control in each test series to get the ratio value, as recommended in the literature ([@b3]). A sample was considered to have increased GP-specific PA-IgG when the ratio was ≥2.0.

### Controls for the MAIPA

Platelets with GP IIbIIIa-specific PA-IgG (anti-HPA-1a sensitized platelets) and platelets with increased GP V-specific PA-IgG ([@b17]) were used as controls to monitor the measuring range of the assay.

Comparability of platelet size measurements by two cell counters and flow cytometry
-----------------------------------------------------------------------------------

In preliminary experiments, the platelet count and mean platelet volume (MPV) of 52 consecutive patient samples were determined both with an electric cell counter applying the impedance method (Medonic, Solna, Sweden) and another cell counter applying the hydrodynamic focusing method (Sysmex XT-2000i, Sysmex Corporation, Kobe, Japan). The results correlated well (*n* = 52; *R* = 0.954, data not shown). The impedance method spared the samples of thrombocytopenic patients. Platelet size (MPV, range 10--16 fl; impedance method) correlated well with the mean of FSC (range 268--552) obtained by flow cytometry (*n* = 32; *R* = 0.834; data not shown). The reference range of healthy control samples (*n* = 40) was 7--10 fl.

Quality assurance of the methods
--------------------------------

Westgard multirule quality control rules 1~3s~, 2~2s~, and 4~1s~ were applied to control results to detect random and systematic errors ([@b37]).

Precision, cut-off values and reference intervals of the PA-IgG assay
---------------------------------------------------------------------

The precision of the PA-IgG method measured as intra-assay and inter-assay repeatability of control samples varied at low level from 1.9% to 4.5% and at high level from 0.4% to 1.6% ([Table 1](#tbl1){ref-type="table"}). The intra-assay and inter-assay repeatability of the GP IIbIIIa and/or IbIX- and GP V-specific determinations of PA-IgG were 5.8% and 12%, which is typical of ELISA methods.

###### 

Precision of platelet-associated IgG (PA-IgG) and glycoprotein (GP)-specific assays

         PA-IgG assay   GP-specific assays                                  
  ------ -------------- -------------------- ----- ----- ----- ----- ------ ------
  Low    1.9            2.3                  3.4   4.5   2.5   2.1   5.3    4.5
  High   0.4            0.7                  0.6   1.6   5.8   5.1   12.3   11.5

Values are expressed as precentage (%).

FSC, forward scatter; PA-IgG, platelet associated IgG; MFI, mean fluorescence intensity; GP IIbIIIa and/or IbIX and GP V, glycoprotein specificity of autoantibodies.

Long-term precision was evaluated by monitoring the annual cut-off value of PA-IgG, which was calculated from the results of donor samples (mean+2s; 300--309), and monitoring the stability of the reference interval for the FSC of the healthy control population (mean ± 2s; 310--376; [Table 2](#tbl2){ref-type="table"}).

###### 

Reference intervals of FSC and cut-off values of platelet-associated IgG (PA-IgG)

            Healthy controls         Patients                      
  --- ----- ------------------ ----- ---------- ----- ------ ----- ------
  1   108   318--385           302   1012       389   29.9   291   98.5
  2   102   320--386           309   965        374   27.5   290   75.3
  3   111   306--366           301   866        377   28.0   294   99.2
  4   108   304--387           309   886        374   34.7   333   78.6
  5   112   309--376           300   854        369   30.0   316   69.6

Annual reference intervals (mean ± 2SD) for forward scatter signal distributions of platelets (FSC).

95% cut-off values for PA-IgG (mean+2SD) from healthy control results. Annual control means did not differ statistically from each other (*P* \> 0.999) whereas patient means were higher than the control means (*P* \< 0.0001).

The reference intervals of the FSC and cut-off-values of PA-IgG did not differ statistically significantly during the five consecutive years (*P* \> 0.999, [Table 2](#tbl2){ref-type="table"}). The results indicate good long-term stability. Patient means were analyzed to detect any long-term drift in PA-IgG measurement ([@b7]; [Table 2](#tbl2){ref-type="table"}).

Statistics
----------

Microsoft® Excel 2003 (Microsoft Corporation) and StatsDirect (version 1.8.10) were used for statistical analysis (mean, standard deviation, SD, coefficient of variation, *CV*, and skewness of distribution). The correlations between methods, R^2^, and the significance of R were calculated with multiple linear regression tests. The Mann--Whitney test was used to calculate *P*-values. The kgr ^2^-test was used to study the significance of differences in GP IIbIIIa and/or IbIX and GP V results grouped according to platelet size. *P*-values below 0.05 were considered statistically significant.

RESULTS
=======

Platelet size (FSC) related to PA-IgG
-------------------------------------

In all screened patients, there was more PA-IgG in samples of platelets from patients than of platelets from healthy controls (316 ± 69.6 and 219 ± 40.7, respectively; *P* \< 0.0001; [Figure 3a](#fig03){ref-type="fig"}).

![Cumulative frequency distributions of platelet-associated IgG (PA-IgG; a) and forward scatter signal distribution of platelets (FSC; b) in healthy controls (*n* = 112) and in all screened patients (*n* = 854; *P* \< 0.0001).](clh0029-0433-f3){#fig03}

The mean FSC of the patient population was significantly higher than that of the healthy control population (369 ± 30 and 342 ± 17, respectively; *P* \< 0.0001; [Figure 3b](#fig03){ref-type="fig"}). Thirty-four percent of patient samples were on the upper side of the reference interval (FSC \> 376) and 0.6% below (FSC \< 306).

Of the 854 patient samples, 295 had increased PA-IgG (MFI \> 300; [Figure 1](#fig01){ref-type="fig"}). PA-IgG was directly associated with platelet size within gated platelet populations of both control and patient samples ([Figure 4](#fig04){ref-type="fig"}; *R* = 0.999).

![Association of platelet-associated IgG (PA-IgG; MFI) with platelet size within the platelet populations of study subjects (grouped according to gated regions, see [Figure 2](#fig02){ref-type="fig"}; patients (□); *n* = 54, and healthy controls (□); *n* = 28).](clh0029-0433-f4){#fig04}

GP-specificity of PA-IgG
------------------------

GP IIbIIIa and/or IbIX-specific PA-IgG was detectable in 44 samples (21%) and GP V-specific PA-IgG in 25 of 206 samples (12%). Only low level of GP V-specific PA-IgG was found in five samples without GP IIbIIIa and/or IbIX-specificity. GP IIbIIIa and/or IbIX-specific PA-IgG was directly associated with GP V-specific PA-IgG (*R* = 0.374, data not shown). Altogether GP IIbIIIa and/or IbIX and/or GP V-specific PA-IgG were detected in 49 of 206 samples (24%; [Figure 1](#fig01){ref-type="fig"}).

PA-IgG was directly associated with the presence of GP IIbIIIa and/or IbIX, and/or GP V-specific PA-IgG ([Figure 5a](#fig05){ref-type="fig"}, *R* = 0.769). When compared with healthy control samples, the cumulative frequency distributions of FSC were significantly higher in patients where GP-specific PA-IgG could be studied (*P* \< 0.0001). However, platelets were only slightly larger in patients with GP-specific PA-IgG than in patients without (*n* = 49 and *n* = 157, *P* = 0.048; [Figure 5b](#fig05){ref-type="fig"}).

![The association of GP IIbIIIa/IbIX-specific antibodies and PA-IgG (*n* = 49; (![](clh0029-0433-fu1.jpg)). In addition, low level of GP V-specific PA-IgG was found in five samples without GP IIbIIIa and/or IbIX-specificity (□; a). Cumulative frequency distributions of FSC were significantly higher in patients where GP-specific PA-IgG could be studied (*n* = 49; *P* \< 0.0001). Platelets were only slightly larger in patients with GP-specific PA-IgG than in patients without (*n* = 49 and 157, respectively; *P* = 0.048; b).](clh0029-0433-f5){#fig05}

GP IIbIIIa and/or IbIX, and/or GP V-specific PA-IgG were more frequently detected in patient samples with larger platelets than in samples with normal sized platelets (*P* = 0.045). Thirty two percent of patients with larger platelets had GP-specific antibodies, compared with 19% of patients with platelets of normal size.

Platelet autoantibodies and platelet count
------------------------------------------

The historical platelet nadir recorded in the referrals of the 27 of 44 patients with GP-specific PA-IgG displayed negative correlation with the level of GP IIbIIIa and/or IbIX-specific PA-IgG (*R* = −0.544, data not shown).

DISCUSSION
==========

Monitoring measures of platelet size, such as mean platelet volume ([@b14]; [@b10]; [@b35]), size deviation width (PDW) and platelet large cell ratio (P-LCR; [@b18]), as well as proportion of immature platelet fraction ([@b5]) have been suggested to aid in the diagnosis of thrombocytopenia.

Until now, relatively little attention has been paid to evaluating of platelet size in association with platelet antibody studies ([@b13]; [@b22]). In this study, platelet size (FSC) as well as PA-IgG were statistically higher in patients than in healthy controls on the analysis of PA-IgG. Furthermore, PA-IgG correlated directly with the FSC within platelet populations of both healthy donors and patients. Thus, the larger the platelet was, the more IgG was bound by the cell. As the PA-IgG is indeed related to FSC, it suggests the possibility of estimating the amount of IgG bound per unit platelet surface area ([@b25]). The diagnostic value of platelet size distributions of a sample should be tested in detection of autoantibodies in patients with definitive ITP and other thrombocytopenic states.

The reference ranges of both FSC and PA-IgG in PA-IgG assay remained within narrow limits. To obtain reproducible results for this analysis, it was necessary to perform laboratory measurements in a strictly controlled way. In this context, rules originally developed for quantitative measurements were applied and seemed to work well ([@b7]; [@b37]; [@b8]; [@b26]). This was especially important because international quality assurance for the measurement of platelet autoantibodies is still not available.

In the present study, PA-IgG showed strong direct association with GP IIbIIIa and/or IbIX and/or GP V-specific PA-IgG, which was taken as the gold standard for platelet autoantibody assays. GP-specific autoantibodies have been detected in varying proportions in autoimmune thrombocytopenia ([@b31]). [@b6] reported a positivity rate of 49% in 66 ITP-patients and in 6/15 patients with secondary immune TP. Also, 22% of patients with initial diagnosis of non-immune TP were reported positive. [@b31] studied 282 chronic ITP patients, and 55.4% of them had GP IIbIIIa and/or IbIX-specific PA-IgG. In the present study, GP IIbIIIa/IbIX and/or GP V-specific autoantibodies were observed in a quarter of patients who had sufficient platelets to measure GP-specificity. The low sensitivities of GP-specific PA-IgG may vary according to the selection of the patient population. In a strictly diagnosed ITP with extensive exclusion of other causes of thrombocytopenia, higher sensitivity of GP-specific antibody assay would be expected ([@b31]). Also, the selection of the cut-off value has an influence on the assay sensitivity. The proportion of patients with GP-specific antibodies would have been larger if the cut-off value of +3s (MFI 340) had been used instead of +2s (MFI 300) for PA-IgG. Although GP-specific antibodies were not tested in the patient population without PA-IgG, the probability of finding GP-specific autoantibodies in such patients would have remained low. The previous results from the same laboratory indicated that when applying two standard deviations as the cut-off value only 2% of patients without increased PA-IgG had slightly increased GP-specific antibodies ([@b16]). A suboptimal combination of monoclonal antibodies applied in the detection of GP-specificity might also have contributed to the proportion of samples with GP-specific antibodies.

In the present study, the frequency of GP IIbIIIa and/or IbIX, and/or GP V-specific PA-IgG was statistically higher in patients with larger platelets although the platelets were still within the reference range (FSC). Interestingly, [@b22] reported larger platelet volume in ITP patients without GP IIbIIIa-specific antibodies than in those with GP IIbIIIa-specific antibodies. Their separate analyses of GP IIbIIIa and IbIX specific antibodies may explain the disparity in results.

Glycoprotein IIbIIIa has been shown to carry the most common target antigens in ITP ([@b2]; [@b30]; [@b19]). In addition, GP IbIX is a prominent target antigen ([@b21]). In this study, GP IIbIIIa-specific PA-IgG was measured together with GP IbIX PA-IgG. The significance of GPV-specific PA-IgG remained unclear. Interestingly, antigen-specific assays have been reported to demonstrate high specificity in the diagnosis of ITP ([@b29]; [@b36]).

In conclusion, it was possible to achieve reproducible results in the PA-IgG and GP-specific PA-IgG assays. The high frequency of increased PA-IgG by flow cytometry suggested low specificity as GP-specificity of the antibodies could be demonstrated relatively rarely. Thus every attempt should be made to spare all platelets of the sample for direct measurement of GP-specific PA-IgG. Even if platelet size was measured separately by a hematology analyzer, the results should be analyzed together with the platelet antibody assay. When interpreting the size of platelets, other disorders in addition to ITP that can cause macrothrombocytopenia with shortened platelet survival time have to be kept in mind, e.g. Bernard-Soulier disease ([@b23]). Prospective studies are indicated to test the diagnostic and predictive value of tests for GP-specific antibodies and platelet size in TP patients.
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